Venkatesh Ramesh, Bavaharan Bharathi, Mahendradas Padmamalini, Yadav Naresh Kumar
Department of Retina and Vitreous, Narayana Nethralaya, Bengaluru - 560010, India,
Department of Uvea and Intraocular Inflammation, Narayana Nethralaya, Bengaluru - 560010, India.
Clin Ophthalmol. 2019 Feb 14;13:353-364. doi: 10.2147/OPTH.S159014. eCollection 2019.
Primary vitreoretinal lymphoma (PVRL) is a rare and potentially fatal intraocular malignancy. More than half of PVRL cases eventually involve the central nervous system (CNS). PVRL frequently masquerades as chronic uveitis. Advanced imaging tests, such as optical coherence tomography and fundus autofluorescence, have been applied in the diagnosis of PVRL. Histology and immunohistochemistry, in combination with molecular tests and IL-10 analysis, have been demonstrated as reliable in diagnosing PVRL. Mortality is high in patients with PVRL associated with CNS involvement, and relapses are common. The use of systemic chemotherapy in addition to the local therapies has proved to extend the mean survival time of these patients. Local therapies, including intravitreal injections of methotrexate and/or rituximab and low-dose radiotherapy to the eye, have been shown to be extremely effective in controlling intraocular lymphoma.
原发性玻璃体视网膜淋巴瘤(PVRL)是一种罕见且可能致命的眼内恶性肿瘤。超过半数的PVRL病例最终会累及中枢神经系统(CNS)。PVRL常伪装成慢性葡萄膜炎。先进的影像学检查,如光学相干断层扫描和眼底自发荧光,已应用于PVRL的诊断。组织学和免疫组织化学,结合分子检测和白细胞介素-10分析,已被证明在诊断PVRL方面是可靠的。伴有CNS受累的PVRL患者死亡率很高,且复发很常见。除局部治疗外使用全身化疗已被证明可延长这些患者的平均生存时间。局部治疗,包括玻璃体内注射甲氨蝶呤和/或利妥昔单抗以及对眼睛进行低剂量放疗,已被证明在控制眼内淋巴瘤方面极其有效。